Definition of Response in Randomized Controlled Trials of Medications for Attention-Deficit/Hyperactivity Disorder Across the Lifespan: A Systematic Review
Rattachement africain : gb, it. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Objectives:Randomized controlled trials (RCTs) are the gold standard for evaluating medication efficacy. The absence of a universal definition of treatment response, based on the degree of symptom improvement measured by standardized rating scales in the field of attention-deficit/hyperactivity disorder (ADHD), makes it difficult to compare treatment outcomes across RCTs. Here, we aimed to assess to what extent and how “treatment response” is defined across RCTs of ADHD medications. Methods:We identified eligible RCTs via the MED-ADHD database (https://med-adhd.org/), which compiles RCTs evaluating the efficacy and safety of pharmacological treatments for children, adolescents, and adults with ADHD, based on a comprehensive search in multiple electronic databases, including PubMed, BIOSIS Previews, CINAHL, the Cochrane Central Registry of Controlled Trials, and EMBASE, up to 17 January 2025, alongside additional unpublished information gathered from manufacturers/study authors. Results:Out of 167 RCTs in MED-ADHD, 88 defined treatment response based on reductions in ADHD core symptom severity using rating scale scores. The most frequently used threshold was a ≥30% reduction in attention-deficit/hyperactivity disorder (ADHD-RS) scores, with other RCTs using ≥25%, ≥40%, or ≥50%. In addition, RCTs applied similar cutoff values to alternative scales, including Conner’s Adult ADHD Rating Scale, SNAP-IV, Adult ADHD Investigator Rating Scale, and Wender-Reimherr Adult Attention Deficit Disorder Scale. However, 79 studies did not specify any response threshold. Conclusion:Our review underscores and quantitatively defines the inconsistency in the definition of treatment response across ADHD medication trials, highlighting the urgent need for the field to reach a consensus on the use of a standardized definition of “treatment response” for each rating scale, based on the percentage reduction in ADHD core symptom severity.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Definition of Response in Randomized Controlled Trials of Medications for Attention-Deficit/Hyperactivity Disorder Across the Lifespan: A Systematic Review
- Date Crossref
- 01/08/2025
- Éditeur
- SAGE Publications
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
University of Southampton Centre for Innovation in Mental Health pays non établi dans la noticeUniversité ou école supérieure
-
University of Bari Aldo Moro pays non établi dans la noticeUniversité ou école supérieure
-
Isle of Wight NHS Trust pays non établi dans la noticeÉtablissement de santé
-
School of Psychology pays non établi dans la noticeUniversité ou école supérieure
-
University of Bari “Aldo Moro DIBRAIN - Department of Biomedicine Translational and Neuroscience pays non établi dans la noticeUniversité ou école supérieure
-
Faculty of Medicine Clinical and Experimental Sciences (CNS and Psychiatry) pays non établi dans la noticeUniversité ou école supérieure
-
Hampshire and Isle of Wight Healthcare NHS Foundation Trust pays non établi dans la noticeOrganisation à but non lucratif
Centre for Innovation in Mental Health — University of Southampton, University of Bari Aldo Moro et Isle of Wight NHS Trust, avec 4 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.